Rocio Reategui
Medical Monitor and Clinical Development Consultant at QED Therapeutics - Palo Alto, CA, US
Rocio Reategui's Colleagues at QED Therapeutics
Rocio Reategui's Contact Details
HQ
650-231-4088
650-231-4088
Location
Company
QED Therapeutics
QED Therapeutics
Rocio Reategui's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Rocio Reategui
Rocio Reategui currently works for QED Therapeutics.
Rocio Reategui's role at QED Therapeutics is Medical Monitor and Clinical Development Consultant.
Rocio Reategui's email address is ***@qedtx.com. To view Rocio Reategui's full email address, please signup to ConnectPlex.
Rocio Reategui works in the Research industry.
Rocio Reategui's colleagues at QED Therapeutics are Mehrak Kiankarimi, Daniela Rogoff, Elizabeth Freas, Hao Wang, Francesca Avogadri-Connors, Hiywot Takkele, Sherry Markle and others.
Rocio Reategui's phone number is 650-231-4088